Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 2
Abstract
Biologicals represent the future of pharmaceutical treatments and innovation. Yet, emerging and developing markets lack access to these often essential medicines. Biosimilar development represents a potential solution to this problem, by offering lower cost and improved access, but is also associated with patient safety issues. In order to synergize these divergent challenges, targeted public−private partnerships that bring together shared goals and resources of the public sector, global firms, and local manufacturers need to be explored. Crucial to their success will be equitable intellectual property rights management and coordination and collaboration with effective governance and incentives.
Authors and Affiliations
Timothy Ken Mackey, Bryan A Liang
Keywords
Related Articles
- EP ID EP355162
- DOI 10.5639/gabij.2012.0102.018
- Views 135
- Downloads 0
Current status of biopharmaceuticals in Iran’s pharmaceutical market
The clinical importance of biopharmaceuticals for the management of life threatening diseases is increasing but costs have become a major obstacle to the administration of these medicines, especially in resource limited...
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price and volu...
US state legislation on biosimilars substitution
Despite the fact that US Food and Drug Administration has yet to receive a biosimilars application, many US states have been considering legislation which could potentially limit biosimilars substitution.
A review of generic medicine pricing in Europe
Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review generic medi...
Safety and toxicity of biosimilars—EU versus US regulation
Background: As patents for biological drugs begin to expire, the need for scientific guidance on biosimilar drugs grows increasingly important. The European Medicines Agency provided the first guidelines to cover the app...